Daclizumab (DAC), a humanized monoclonal antibody that binds to the interleukin (IL)-2-receptor alpha chain, was approved in May 2016 for treatment of relapsing-remitting multiple sclerosis (RRMS). Approval was suspended in March 2018 after occurrence of severe liver failure and fatal meningoencephalitis in several patients treated with DAC. We report the clinical, laboratory and neuroimaging findings of 2 patients, who developed hypophysitis about 4 months after cessation of therapy with DAC. This report identifies delayed onset hypophysitis as a previously unrecognized severe side effect of DAC, highlighting the importance of continuous pharmacovigilance and patient monitoring even after cessation of DAC therapy.

中文翻译：

---

达利珠单抗治疗多发性硬化后迟发性垂体炎2例报告

Daclizumab (DAC) 是一种与白细胞介素 (IL)-2-受体α 链结合的人源化单克隆抗体，于 2016 年 5 月被批准用于治疗复发缓解型多发性硬化症 (RRMS)。在几名接受 DAC 治疗的患者发生严重肝功能衰竭和致命性脑膜脑炎后，该批准于 2018 年 3 月暂停。我们报告了 2 名患者的临床、实验室和神经影像学发现，他们在停止 DAC 治疗后约 4 个月出现垂体炎。该报告将迟发性垂体炎确定为 DAC 以前未被认识的严重副作用，强调了即使在 DAC 治疗停止后持续药物警戒和患者监测的重要性。